Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer [0.03%]
携带BRAF突变的结直肠癌对MAPK抑制的反应过程中ETS和MYC核心调控回路重新编程细胞可塑性
Hey Min Lee,Zhao Zheng,Alexey Sorokin et al.
Hey Min Lee et al.
Purpose: Aberrant enhancer dynamics play a critical role in the initiation and progression of colorectal cancer (CRC), particularly in the BRAFV600E-mutated metastatic subtype, which uniquely exhibits a strong epigenetic ...
The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma [0.03%]
晚期黑色素瘤和肾细胞癌患者接受肌肉注射个体化新抗原合成长肽疫苗Ⅱ期IMPACT试验
Nussara Pakvisal,Piriya Wongkongkathep,Worawan Bunrasmee et al.
Nussara Pakvisal et al.
Purpose: To evaluate safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. ...
Enfortumab vedotin plus pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: results from EV-202 cohort 9 [0.03%]
恩沃单抗联合派姆单抗治疗复发或转移性头颈部鳞癌的1线治疗：EV-202队列9的研究结果
Paul L Swiecicki,Glenn J Hanna,Jessica L Geiger et al.
Paul L Swiecicki et al.
Purpose: To assess safety and efficacy of enfortumab vedotin (EV) and pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). ...
Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial [0.03%]
本ctla-4抑制剂诱导的嗜酸性粒细胞相关型皮炎的二期临床试验：Benralizumab治疗的安全性和有效性
Mario E Lacouture,Alexander Pan,Tara Maier et al.
Mario E Lacouture et al.
Purpose: Eosinophil-related cutaneous adverse events (ercAEs) are common following systemic cancer therapies and often impact health-related quality of life (HRQoL). Here we investigate the efficacy and safety of benraliz...
Retraction: Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma [0.03%]
撤回：安罗替尼联合替莫唑胺治疗复发胶质母细胞瘤患者的安全性及有效性
Qingsheng Xu,Kaiyuan Huang,Xiangqi Meng et al.
Qingsheng Xu et al.
Editor's Note: Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo [0.03%]
编者按：富马酰亚胺基羟胺酸抗甲状腺癌的体内外实验研究
Quang T Luong,James O&#x;Kelly,Glenn D Braunstein et al.
Quang T Luong et al.
Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy [0.03%]
早期ctDNA对局部晚期和寡转移性肺癌放疗预后的预测价值
Ayesha Hashmi,Jessica Linford,Pradeep S Chauhan et al.
Ayesha Hashmi et al.
Purpose: Circulating tumor fraction estimate (ctFE) is a machine learning-derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre- and early on-treatment ctFE could robustly risk-stratif...
Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases [0.03%]
1427例胃肠间质瘤的真实世界队列的多组学图谱
César Serrano,Andrew Elliott,David Gómez-Peregrina et al.
César Serrano et al.
Purpose: Gastrointestinal stromal tumor (GIST) is a genomically-driven neoplasm with a genetic profile that determines the clinical course of the disease. However, currently available molecular data is limited due to the ...
Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target [0.03%]
前列腺癌患者的组织评估鉴定出B7-H3是一个广谱表达的雄激素调控联合治疗靶点
Shivang Sharma,Nikita Mundhara,Emirhan Tekoglu et al.
Shivang Sharma et al.
Purpose: Advanced Prostate Cancer (PCa) management suffers from therapeutic resistance due to naturally transient or AR-dependent expression of clinically actionable surface targets. We aimed to identify the most promisin...
Tumor microenvironment gene engineering with LOAd703 in patients with solid malignancies: LOKON002 phase I/IIb clinical trial [0.03%]
LOKON002 I 期/ IIb 临床试验：在实体瘤患者中使用 LOAd703 肿瘤微环境基因工程疗法
Amanda Hahn,Sandra Irenaeus,Linda C Sandin et al.
Amanda Hahn et al.
Purpose: Patients with advanced cancer have a poor prognosis and need for novel treatments. LOAd703 is a tumor microenvironment (TME) gene engineering viral vector encoding genes targeting the CD40 and 4-1BB pathways. In ...